NTAGI Approves SII's Covovax COVID-19 Vaccine for 12-17 Age

Earlier this month in an Exclusive Interview with ANI, Serum Institute of India (SII) CEO Adar Poonawalla said, "Covovax will be used for children. It has been approved by DCGI and we're waiting for the Government of India to allow us to put it on the CoWIN app to make it available to everyone." NTAGI Approves SII's Covovax COVID-19 Vaccine for 12-17 Age Group: Sources.

Related Keywords

Australia , India , New Delhi , Delhi , Bharat , Narendra Modi , Adar Poonawalla , Adar Poonawala , Serum Institute Of India Covovax , National Technical Advisory Group On Immunisation , Serum Institute Of India , National Technical Advisory Group , Serum Institute , Prime Minister Narendra Modi , Drugs Controller General , Exclusive Interview , Bharat Biotech Must Address , Covaxin Supply Suspension , Avoid Emergency Use Listing Cancellation , Covid 19 Vaccine , Covovax , Covovax Vaccine , Cowin App , Immunisation ,